RA Patients in Great Need of New Treatment Options
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’...
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’...
As drugs in psoriasis and psoriatic arthritis therapy areas nab new indications that crisscross the two categories, dermatologists and rheumatologists...
The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists...
Bristol Myers Squibb is the surprise winner in an emerging rheumatoid arthritis (RA) market dynamic as doctors eschew new JAK...
Potential paradigm shifts in the post-TNF and later-line setting leave ample opportunity for alternate mechanism agents EXTON, Pa., April 6,...
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well...
By: Eric John Pandemic aside (if you can imagine that), launching a drug in the pharmaceutical industry is no walk...
Authors: Maxine Yarnall, Tucker Hurtado, Vibeke Strand BACKGROUND and AIMS: present significant challenges in management. This study was to...
Authors: Maxine Yarnall BACKGROUND and AIMS: Treatment for psoriatic arthritis (PsA) is largely accounted for by TNFs and their...
Authors: Maxine Yarnall, Chrystal Ferguson BACKGROUND and AIMS: As use of Januse Kinase Inhibitor (JAKi) therapies in rheumatoid arthritis...
From: FiercePharma By: Angus Liu A recent survey of 100 high-volume U.S. rheumatologists that Piper Sandler conducted with Spherix...